Choose Language
Select a language for news translation.
The ad jingle you just can’t get out of your head — no matter how hard you may try — is staying on the air for now in California
Written by Catie Hogan for The Motley Fool -> HPE's networking revenue increased 148% in the second quarter of 2026. Dell's AI server revenue grew an eye-pop…
Applied Aerospace & Defense, Inc. (NYSE: AADX ) was among the stocks on which Jim Cramer gave his opinion, as he warned that increased AI-related spending migh…
Written by Geoffrey Seiler for The Motley Fool -> Microsoft continues to see strong growth with both its software and cloud businesses. ServiceNow is seeing …
Written by Jeff Siegel for The Motley Fool -> Eli Lilly now controls roughly 60% of the GLP-1 market. International growth could become Lilly's next major ca…
All the familiar faces who took uncorroborated allegations against Brett Kavanaugh at their face are now attacking or dismissing the multitude of allegations a…
Facebook has long been filled with feeds of clickbait articles. Now, Meta is making its own clickbait articles with AI. The standalone Meta AI app now has a "F…
In her run for South Carolina governor she’s battling several controversies and headwinds — including the president endorsing her opponent.
Written by Reuben Gregg Brewer for The Motley Fool -> Wall Street likes stories, and a big one today is the huge demand for GLP-1 weight-loss drugs. Novo Nor…
That is the frustrating math facing many U.S. buyers in 2026. Mortgage rates may ease. Some markets may show better affordability. Incomes may rise. But for th…
A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop b…
